Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRDT | Q58F21 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21693082 | 0.95 | BRDT (0.35) | BRDTPIM1GPR3ALOX5ADRA2C | |
| SCHEMBL21693072 | 0.93 | ADRA2C (0.40) | BRDTADRA2CADORA2AADORA1GABRG2 | |
| SCHEMBL21692530 | 0.91 | KDM4A (0.35) | BRDTPIM1GPR3ALOX5GABRG2 | |
| SCHEMBL21692337 | 0.90 | SQOR (0.38) | BRDTPIM1ADORA2AADORA1SLC22A12 | |
| SCHEMBL21692596 | 0.90 | ALOX5 (0.35) | BRDTPIM1GPR3ALOX5ADRA2C | |
| SCHEMBL21693152 | 0.90 | ALOX5 (0.35) | BRDTPIM1GPR3ALOX5ADRA2C | |
| SCHEMBL21693074 | 0.88 | GPR3 (0.36) | BRDTGPR3ALOX5ADRA2CADORA2A | |
| SCHEMBL21692616 | 0.88 | ALOX5 (0.41) | BRDTGPR3ALOX5 | |
| SCHEMBL21693069 | 0.88 | GABRG2 (0.39) | BRDTADRA2CADORA2AADORA1GABRG2 | |
| SCHEMBL21692533 | 0.86 | PRSS12 (0.37) | BRDTPIM1GPR3ALOX5GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053228-B2 | Condensed cyclic compound, composition including the condensed cyclic compound, and organic light-emitting device including the condensed cyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-07-06 | — | — | US | disclosed |
| US-20200031812-A1 | CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE CONDENSED CYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND | SAMSUNG SDI CO., LTD. (KR) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053228-B2 | Condensed cyclic compound, composition including the condensed cyclic compound, and organic light-emitting device including the condensed cyclic compound | CCNL2, ARL1, CRY1 | BRDT 1092/4885PIM1 3916/4885GPR3 1463/4885 |
| US-20200031812-A1 | CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE CONDENSED CYCLIC COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND | CCNL2, ARL1, CRY1 | BRDT 1092/4885PIM1 3916/4885GPR3 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.